Beactica Therapeutics Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 6

Beactica Therapeutics General Information

Description

Developer of a medicine discovery platform designed to facilitate the treatment of glioblastoma and other cancers. The company's platform offers protein-based therapeutics that regulate the expression of disease-associated proteins in order to change the chromatin configuration that governs the regulation of deoxyribonucleic acid transcription and improve the immune system's ability to fight cancer, enabling medical practitioners to treat patients with cancer with improved efficiency and lower risks.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Uppsala Business Park
  • Rapsgatan 7
  • 754 50 Uppsala
  • Sweden
+46 018-56
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Uppsala Business Park
  • Rapsgatan 7
  • 754 50 Uppsala
  • Sweden
+46 018-56

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Beactica Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private 01-Apr-2026 Completed Generating Revenue
10. Later Stage VC 01-Jan-2021 Completed Generating Revenue
9. Later Stage VC 01-Jan-2020 Completed Generating Revenue
8. Grant 18-Jun-2019 Completed Pre-Clinical Trials
7. Later Stage VC 04-Jun-2019 Completed Pre-Clinical Trials
6. Grant 23-Mar-2018 Completed Pre-Clinical Trials
5. Later Stage VC 15-Dec-2014 Completed Pre-Clinical Trials
4. Accelerator/Incubator Completed Pre-Clinical Trials
3. Grant 20-Nov-2014 $407K Completed Pre-Clinical Trials
2. Grant 14-Sep-2007 $187K Completed Pre-Clinical Trials
To view Beactica Therapeutics’s complete valuation and funding history, request access »

Beactica Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
To view Beactica Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Beactica Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a medicine discovery platform designed to facilitate the treatment of glioblastoma and other cancers. The c
Drug Discovery
Uppsala, Sweden
16 As of 2025

Basel, Switzerland
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Beactica Therapeutics Competitors (100)

One of Beactica Therapeutics’s 100 competitors is TOLREMO therapeutics, a Venture Capital-Backed company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TOLREMO therapeutics Venture Capital-Backed Basel, Switzerland
Numerion Labs Venture Capital-Backed San Francisco, CA
Biosceptre Venture Capital-Backed Cambridge, United Kingdom
Cellestia Venture Capital-Backed Basel, Switzerland
Plexium Venture Capital-Backed San Diego, CA
You’re viewing 5 of 100 competitors. Get the full list »

Beactica Therapeutics Patents

Beactica Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024277772-A1 Aromatic amides and conjugates thereof as binders to tead Pending 24-May-2023
EP-4720044-A1 Aromatic amides and conjugates thereof as binders to tead Pending 24-May-2023
WO-2024240840-A1 Aromatic amides and conjugates thereof as binders to tead Inactive 24-May-2023 C07D223/12

Beactica Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Beactica Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
SWElife Government
Flerie Venture Capital Minority
M2Capital PE/Buyout Minority
Paab Venture Capital Minority
Unionen Corporation Minority
You’re viewing 5 of 6 investors. Get the full list »

Beactica Therapeutics FAQs

  • When was Beactica Therapeutics founded?

    Beactica Therapeutics was founded in 2006.

  • Where is Beactica Therapeutics headquartered?

    Beactica Therapeutics is headquartered in Uppsala, Sweden.

  • What is the size of Beactica Therapeutics?

    Beactica Therapeutics has 16 total employees.

  • What industry is Beactica Therapeutics in?

    Beactica Therapeutics’s primary industry is Drug Discovery.

  • Is Beactica Therapeutics a private or public company?

    Beactica Therapeutics is a Private company.

  • What is Beactica Therapeutics’s current revenue?

    The current revenue for Beactica Therapeutics is .

  • How much funding has Beactica Therapeutics raised over time?

    Beactica Therapeutics has raised $2.61M.

  • Who are Beactica Therapeutics’s investors?

    SWElife, Flerie, M2Capital, Paab, and Unionen are 5 of 6 investors who have invested in Beactica Therapeutics.

  • Who are Beactica Therapeutics’s competitors?

    TOLREMO therapeutics, Numerion Labs, Biosceptre, Cellestia, and Plexium are some of the 100 competitors of Beactica Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process